TerminatedEarly Phase 1

Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery

Stopped: Drug supply issues

United States34 participantsStarted 2021-06-16

Plain-language summary

The purpose of this study is to evaluate the use of locally injected tranexamic acid (TXA) under the skin during Mohs micrographic surgery for removal of skin cancers in patients on anticoagulation. TXA may be helpful in reducing bleeding and pain during surgery, and may also lead to fewer post-operative complications following surgery such as graft loss, specifically in patients on blood-thinners.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Must be on systemic anticoagulation therapy (indirect or direct anticoagulants or anti-platelet agents) * Must be scheduled for Mohs surgery at the University of Massachusetts Department of Dermatology Exclusion Criteria: * History of hypercoaguable disorder (e.g. Factor V Leiden Deficiency) * History of deep vein thrombosis or pulmonary embolism * Systolic blood pressure greater than 200 on day of surgery * Known allergy to TXA * Currently taking systemic retinoids * Unable to consent * Pregnant women * Prisoners

What they're measuring

Postoperative Complications

Timeframe: From day of surgery to 12 weeks post-operation

Trial details

NCT IDNCT04630886

SponsorRiley McLean

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-16

View on ClinicalTrials.gov More Skin Neoplasms trials